Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

PHYND launches free game streaming beta on Samsung Smart TVs in the U.S., no console or subscription needed.

Others
18 May 2026
Unknown
View Source
Bullish
pluang ai news

PHYND has launched its beta game streaming service on Samsung Gaming Hub for U.S. users, offering free access to a variety of console-quality games without requiring a console, download, or subscription. Available on Samsung Smart TVs from 2022 and newer, the service features titles from global studios across multiple genres, aiming to make gaming as accessible as watching TV. This launch represents PHYND's first step in expanding its platform and game catalog, providing new opportunities for developers and a seamless gaming experience for players. Users can join a waitlist for expanded availability and upcoming features via the PHYND website.

More News

Pepeto presale nears Binance listing, promising bigger returns than XRP's forecasted growth.

Pepeto presale nears Binance listing, promising bigger returns than XRP's forecasted growth.

Pepeto is preparing for a Binance listing amid a forming crypto bull run, with its presale raising over $10 million and showing strong community growth. The project offers a zero-fee exchange with AI contract screening and cross-chain capabilities, a...

Market News
Bullish
12 minutes ago
SharonAI reports Q1 loss but sees strong AI cloud growth and data center expansion.

SharonAI reports Q1 loss but sees strong AI cloud growth and data center expansion.

SharonAI Holdings reported a first-quarter EPS loss of $1.43, slightly worse than last year's $1.34 loss, with revenue declining to $294,014 from $325,092. Despite this, the company highlighted strong demand for its AI cloud services and announced an...

Company Fundamentals
Bullish
21 minutes ago
ImmunityBio gains exclusive U.S. rights to Tokyo-172 BCG for bladder cancer after positive Phase 3 trial.

ImmunityBio gains exclusive U.S. rights to Tokyo-172 BCG for bladder cancer after positive Phase 3 trial.

ImmunityBio secured exclusive U.S. development and supply rights for the Tokyo-172 strain of BCG, an investigational bladder cancer therapy not yet FDA-approved. This follows positive Phase 3 trial results showing Tokyo-172 BCG is as effective as the...

Market News
Bullish
51 minutes ago
LanzaTech plans $20M stock offering to strengthen finances amid ongoing losses and operational progress.

LanzaTech plans $20M stock offering to strengthen finances amid ongoing losses and operational progress.

LanzaTech announced a registered direct offering of common stock to raise about $20 million, aiming to improve its financial position. Despite a 66% stock drop over the past year and a first-quarter loss of $1.77 per share, the company is making oper...

Technical Signals
Neutral
1 hour ago
Baidu beats earnings estimates as AI business drives revenue growth past $4.6B.

Baidu beats earnings estimates as AI business drives revenue growth past $4.6B.

Baidu reported strong Q1 2026 earnings, with EPS of $1.75 surpassing analyst expectations of $1.67 and revenue of $4.65 billion beating estimates of $4.54 billion. The company's rapid growth in AI-powered cloud services now accounts for over half of ...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App